Avadel Pharmaceuticals PLC (AVDL)
11.82
+0.16
(+1.42%)
USD |
NASDAQ |
Nov 22, 13:33
Avadel Pharmaceuticals Revenue (Quarterly): 50.02M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 50.02M |
| June 30, 2024 | 41.50M |
| March 31, 2024 | 27.18M |
| December 31, 2023 | 19.45M |
| September 30, 2023 | 7.014M |
| June 30, 2023 | 1.496M |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 10.09M |
| March 31, 2020 | 12.24M |
| December 31, 2019 | 11.00M |
| September 30, 2019 | 14.23M |
| June 30, 2019 | 17.55M |
| March 31, 2019 | 16.44M |
| December 31, 2018 | 20.92M |
| September 30, 2018 | 19.83M |
| Date | Value |
|---|---|
| June 30, 2018 | 29.23M |
| March 31, 2018 | 33.29M |
| December 31, 2017 | 34.75M |
| September 30, 2017 | 39.68M |
| June 30, 2017 | 46.31M |
| March 31, 2017 | 52.51M |
| December 31, 2016 | 43.08M |
| September 30, 2016 | 32.09M |
| June 30, 2016 | 38.86M |
| March 31, 2016 | 36.22M |
| December 31, 2015 | 44.57M |
| September 30, 2015 | 47.31M |
| June 30, 2015 | 48.60M |
| March 31, 2015 | 32.73M |
| December 31, 2014 | -9.31M |
| September 30, 2014 | 7.028M |
| June 30, 2014 | 4.318M |
| March 31, 2014 | 4.578M |
| December 31, 2013 | -12.08M |
| September 30, 2013 | 5.583M |
| June 30, 2013 | 5.541M |
| March 31, 2013 | 5.14M |
| December 31, 2012 | -11.26M |
| September 30, 2012 | 5.398M |
| June 30, 2012 | 6.033M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.496M
Minimum
Jun 2023
50.02M
Maximum
Sep 2024
20.00M
Average
12.24M
Median
Mar 2020
Revenue (Quarterly) Benchmarks
| Jazz Pharmaceuticals PLC | 1.055B |
| Medtronic PLC | 8.403B |
| Alkermes PLC | 378.14M |
| Perrigo Co PLC | 1.088B |
| Iterum Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.625M |
| Total Expenses (Quarterly) | 50.35M |
| EPS Diluted (Quarterly) | -0.03 |
| Enterprise Value | 1.058B |
| Gross Profit Margin (Quarterly) | 87.70% |
| Profit Margin (Quarterly) | -5.25% |
| Earnings Yield | -6.43% |
| Normalized Earnings Yield | -6.522 |